(Q34274614)

1 August 2017

Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis (English)

1 reference

1 August 2017

0 references

1

Stephan Harbarth

1 reference

1 August 2017

6

Didier Pittet

1 reference

1 August 2017

2

Jorge Garbino

1 reference

1 August 2017

Jérome Pugin

3

1 reference

1 August 2017

Daniel Lew

5

1 reference

1 August 2017

Jacques A. Romand

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14599631

28 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

1 August 2017

https://api.elsevier.com/content/article/PII:S0002934303005059?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

https://api.elsevier.com/content/article/PII:S0002934303005059?httpAccept=text/plain

28 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

American Journal of Medicine

28 March 2024

published in

1 reference

1 August 2017

115

1 reference

1 August 2017

529-535

1 reference

1 August 2017

7

1 reference

The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults.

1 August 2017

1

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients

28 March 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Appropriate use of antimicrobial agents: challenges and strategies for improvement

28 March 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients

28 March 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Analysis of 1,186 Episodes of Gram-Negative Bacteremia in Non-University Hospitals: The Effects of Antimicrobial Therapy

28 March 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

28 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

28 March 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients

28 March 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group

28 March 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis

28 March 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit

28 March 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Outcome of postoperative pneumonia in the Eole study

28 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Long-term survival and function after suspected gram-negative sepsis.

28 March 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

28 March 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

28 March 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group

28 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

28 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Impact of immunomodulating therapy on morbidity in patients with severe sepsis

28 March 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Microbiologic findings and correlations with serum tumor necrosis factor-alpha in patients with severe sepsis and septic shock

28 March 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care

28 March 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.

28 March 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Estimating causal effects from large data sets using propensity scores

28 March 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Rare outcomes, common treatments: analytic strategies using propensity scores.

28 March 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam

28 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group

28 March 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection

28 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Management of Suspected Ventilator-Associated Pneumonia

28 March 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: does antimicrobial choice make a difference?

28 March 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome

28 March 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Early goal-directed therapy in the treatment of severe sepsis and septic shock

28 March 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia

28 March 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Survival of patients with bacteraemia in relation to initial empirical antimicrobial treatment

28 March 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Antimicrobial misuse in patients with positive blood cultures.

28 March 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance

28 March 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2003.07.005

28 March 2024

Identifiers

1 reference

1 August 2017

1 reference